Polypill as a means of population pharmacological prevention of cardiovascular diseases

Non-communicable diseases, among which arterial hypertension and ischemic heart disease are the predominant contributors to disability and mortality, have long been identified as a strategic target of preventive intervention in our country. The situation is aggravated by covid-19 associated mortality, which is characterized by delayed dynamics and is largely related to cardiovascular. Excess mortality, in the structure of which cardiovascular diseases are leading, requires new solutions. One of them is population pharmacoprevention, based on the use of complex fixed combinations of drugs targeting different risk factors, as arterial hypertension and dyslipidemia, as most important. This concept, which logically follows from modern realities, is in contradiction with the existing approach of personalized therapy in high/very high risk groups, because of its complexity, leading to patients noncompliance. The new system of cardiovascular risk stratification SCORE 2 introduced in the Russian Federation significantly contributes to the spread of the concept of polypills as a unified approach primarily in the most vulnerable population of males 50 years and older.